Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

• Status: Completed
• Trial end date: 2018-11-14
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim

Criteria

Inclusion Criteria:

• Male or female patients, 18 to 65 years of age at screening.

• Palmoplantar Pustulosis

• Further inclusion criteria apply

Exclusion Criteria:

• Presence or known history of anti- Tumor necrosis factor (TNF)-induced Palmoplantar Pustulosis (PPP)-like disease.

• Active or latent tuberculosis

• Further exclusion criteria apply